Nurse Navigators Play Key Role in the Evolution of a Navigation Database: The Fox Chase Cancer Center Journey

August 2012 Vol 3, No 4
Bonnie J. Miller, RN, BSN, OCN, FAAMA
Fox Chase Cancer Center, Philadelphia, Pennsylvania
Tracey Newhall, RN, BS, OCN
Fox Chase Cancer Center, Philadelphia, Pennsylvania
Jessie Schol, RN, BSN, OCN
Fox Chase Cancer Center, Philadelphia, Pennsylvania
Caryn Vadseth, BSN, RN, OCN, ONN-CG(T)
Oncology Navigation Nurse Manager
Sidney Kimmel Cancer Center
Joanne Stein, RN
Fox Chase Cancer Center, Philadelphia, Pennsylvania

Background: This program illustrates the impact of contributions by nurse navigators to the development of a database influencing cancer care across the continuum. Oncology nurse navigation continues to grow in importance as nurses assist with the diverse needs of cancer patients. Demonstrating the impact of nurse navigation along the continuum of care not only supports better outcomes but allows for sustainment of a navigation program. An effective tool to document and measure accurate and timely interventions that is not labor intensive is critical.

Methods: A nurse navigation program piloted and tested several database programs starting with an Excel spreadsheet, which evolved to an ACCESS Database. Nurse navigators, nursing administration, and the IT research team developed a Web-based application. This application links existing systems within the institution, thus supporting clinical care. It also provides the ability to run reports allowing administrators to demonstrate the impact of navigation through the continuum of care and on the return on investment. All navigators utilize this application and actively participate in the continued upgrades and modifications meeting navigation program needs.

Results: By instituting this application, time and effort spent by the nurse navigator in documentation has decreased. This allows navigators to focus on patient needs while permitting accurate, timely, and effective documentation. Data collected and reported have helped sustain nurse navigators in breast cancer programs and provided support for proposals for additional navigators in gynecologic oncology, head and neck cancer, thoracic cancer, gastrointestinal cancer, and infusion room settings.

Conclusion: The database allows measurement of specific goals related to timeliness of patient care from initial call to first appointment and referral to clinical trials. The database assists with the evaluation of interdisciplinary metrics and goals across disease sites. The navigation database was developed by oncology nurse navigators to provide an avenue of documentation that is tailored to the needs of the oncology patient.

Oncology nursing practice includes patient education and advocacy. The evolution of the development of the navigation database demonstrates the impact that oncology nurses can have in creating a patient documentation tool while providing data that impact sustainability of this important role. Average retention rates across all disease sites is 68%. This information gleaned from the navigation database supports the nurse navigator role in our institution.

Information we are able to collect in the database demonstrates return on investment for patients touched by navigation and is reflected in retention rates, multidisciplinary care, clinical trial accruals, and streamlined timeliness of care.

Related Articles
Assessment of Side Effects (SEs) Impacting Quality of Life (QOL) in Patients (Pts) Undergoing Treatment (tx) for Advanced Breast Cancer (ABC) in Clinical Practice: A Real-World (RW) Multicountry Survey
November 2022 Vol 13, No 11
To examine how SEs impacting QOL in pts with ABC are perceived.
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non–Small-Cell Lung Cancer (NSCLC) Enrolled in VISION
November 2022 Vol 13, No 11
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
November 2022 Vol 13, No 11
MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.1,2
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State